Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Adverse drug events

Diabetes drugs with antioxidant properties linked to spread of cancer

Researchers call for caution when using DPP-4 inhibitors to treat patients with existing cancer.

MRI of metastasis in the brain

Source: BSIP SA / Alamy Stock Photo

Researchers found that dipeptidyl peptidase–4 inhibitors increased the risk of existing tumours metastasising. Pictured, an MRI scan of tumour metastasis in the brain

Some recent treatments for diabetes may enhance the spread of cancer, suggest the results of a study conducted in mice.

Researchers found that the dipeptidyl peptidase (DPP)–4 inhibitors saxagliptin and sitagliptin, as well as the antioxidant alpha-lipoic acid, increased the risk of existing tumours metastasising.

While the drugs do not increase the initial risk of developing cancer, the finding has led the researchers to call for caution when using the drugs to treat patients with existing cancer.

“The results we present here indicate that saxagliptin and sitagliptin enhance cancer cells’ mobility and invasive capacity and may promote tumour metastasis,” say the researchers, led by Hongting Zheng from the department of endocrinology at Xinqiao Hospital in Chongqing, China.

Diabetes is increasing among the general population — the World Health Organization estimates that the number of adults living with the disease globally has quadrupled since 1980 to 422 million adults — and the disease is associated with an increased risk of cancer. Research has examined the effect of diabetes drugs on the risk of developing cancer but the effect these treatments has on cancer once it is established has not been assessed. Previous research has found that antioxidants can increase the spread of cancer by making cancerous cells more resistant to oxidative stress, which would ordinarily cause damage to the cells and hinder their survival.

Zheng’s team performed a meta-analysis to assess the effect of DPP-4 inhibitors on the incidence of cancer and found no increase. However, using in vitro cell cultures of cancers commonly associated with diabetes, they found that saxagliptin and sitagliptin markedly increased migration and invasion of the cells. In a tumour-bearing mouse model, the drugs significantly increased the number of metastatic nodules in the liver and lungs.

The researchers showed that the drugs’ effects were likely to be mediated through activation of the nuclear factor E2–related factor 2 (Nrf2) pathway. Nrf2 is one of the cell signalling pathways that responds to antioxidants by helping to protect cells – its activation was also correlated with tumour spread.

The antioxidant alpha-lipoic acid is used by some people with diabetes to relieve neuropathic pain, so the researchers tested its ability to enhance metastasis. Similarly to saxagliptin and sitagliptin, alpha-lipoic acid activated Nrf2 and increased the burden of metastatic nodules in the mouse model.

The researchers, reporting the results in Science Translational Medicine[1] (online, 13 April 2016), conclude: “Our findings suggest that antioxidants that activate NRF2 signalling may need to be administered with caution in cancer patients, such as diabetic patients with cancer. Moreover, NRF2 may be a potential biomarker and therapeutic target for tumour metastasis.”

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2016.20201034

Readers' comments (1)

  • Your article is very useful and informative, quite liked to read it, I recently wrote an article about Walking Fitness for Diabetes, can be read here:

    Unsuitable or offensive? Report this comment

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Physicochemical Principles of Pharmacy

    Physicochemical Principles of Pharmacy

    This established textbook covers every aspect of drug properties from the design of dosage forms to their delivery by all routes to sites of action in the body.

    £47.00Buy now
  • Drugs and the Liver

    Drugs and the Liver

    Drugs and the Liver assists practitioners in making pragmatic choices for their patients. It enables you to assess liver function and covers the principles of drug use in liver disease.

    £37.00Buy now
  • Drugs in Use

    Drugs in Use

    Optimise drug therapy for your patients. These case studies help you bridge the gap between theoretical medicines knowledge and practical applications.

    £42.00Buy now
  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £37.00Buy now
  • Non-prescription Medicines

    Non-prescription Medicines

    Reviews over-the-counter medicines, arranged by the conditions they are licensed to treat. Includes product recommendations.

    £37.00Buy now
  • International Research in Healthcare

    International Research in Healthcare

    Guidance for students or researchers undertaking a multi-centre research project in health services, medicines use and professional practice.

    £37.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • MRI of metastasis in the brain

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.